Crinetics Pharmaceuticals, Inc. filings document a commercial-stage pharmaceutical company focused on endocrine diseases and endocrine-related tumors. Its 8-K reports include financial results and business updates tied to PALSONIFY product revenue, clinical development activity, regulatory matters, and corporate presentations. The filings also identify the company’s common stock, traded under CRNX on the Nasdaq Global Select Market.
Crinetics’ regulatory record also includes proxy materials covering governance and executive compensation, as well as current reports on officer responsibilities, executive departures, consulting arrangements, and changes in the company’s independent registered public accounting firm. These disclosures place PALSONIFY commercialization and endocrine pipeline development within formal reporting categories for operations, governance, controls, and capital-market status.
Crinetics Pharmaceuticals, Inc. reported that Chief Commercial Officer Isabel Kalofonos received new equity awards on February 23, 2026. She was granted stock options for 55,000 shares of common stock at an exercise price of $0.00 and 34,000 shares of common stock as restricted stock units.
The restricted stock units represent the right to receive common shares, with 25% vesting annually beginning on March 1, 2027. The stock option vests in forty-eight equal monthly installments starting from February 23, 2026, aligning the CCO’s compensation with long-term company performance through time-based vesting.
Crinetics Pharmaceuticals, Inc. (CRNX) received an updated ownership disclosure from Farallon-affiliated investment funds and managers. The Schedule 13G/A (Amendment No. 1), triggered by a 12/31/2025 event date, reports aggregate beneficial ownership of 8,024,098 common shares, representing 8.5% of the company.
The largest single holder listed is Farallon Healthcare Partners Master, L.P., with 4,682,318 shares, or 4.9% of the class. Farallon Partners, L.L.C. is reported as beneficial owner of 7,826,338 shares, or 8.2%. All Farallon entities report only shared, and no sole, voting or dispositive power.
The amendment updates the group’s internal governance. Effective 1/1/2026, Avner A. Husen became a member/manager of the Farallon general partner entities and may be deemed a beneficial owner of the Farallon funds’ shares. Effective 12/31/2025, Richard B. Fried, Rajiv A. Patel and William Seybold ceased those roles and may no longer be deemed beneficial owners. The reporting persons file under Rule 13d-1(c) and certify the shares are not held to change or influence control of Crinetics.
CRNX insider Dana Pizzuti has filed a Form 144 to sell 10,000 shares of common stock. The planned sale, through Morgan Stanley Smith Barney LLC on NASDAQ around February 2, 2026, has an aggregate market value of 499,400.00, with 94,891,840 shares outstanding.
The 10,000 shares were acquired the same day via a cash exercise of stock options. Over the prior three months, Pizzuti sold a total of 15,000 common shares in three 10b5-1 plan transactions, with gross proceeds of 232,590.50, 225,091.50, and 213,300.50.
Crinetics Pharmaceuticals, Inc. reported a leadership title change for one of its senior executives. Effective January 2, 2026, Jeff Knight’s role was updated from Chief Operating Officer to Chief Development and Operating Officer. The board of directors approved this change on January 20, 2026, to better reflect his existing responsibilities and scope of duties.
The company stated that there were no changes to Mr. Knight’s compensation arrangements in connection with this new title. Crinetics also confirmed that there are no arrangements or understandings with any other person related to his selection for this role, no family relationships with any director or executive officer, and no reportable related party transactions involving him. His business experience is described in the company’s 2025 proxy statement, which is incorporated by reference.
Crinetics Pharmaceuticals reported preliminary and unaudited fourth-quarter 2025 net product revenue from PALSONIFY (paltusotine) of over $5.0 million for the three months ended December 31, 2025. This early revenue snapshot reflects sales of its commercial product but may change once full year-end financial closing procedures, management review and internal control processes are completed.
The company also provided a business update at the 44th annual J.P. Morgan Healthcare Conference, using a corporate slide deck furnished as an exhibit. All of this information is being furnished rather than filed under securities laws, and Crinetics emphasized that forward-looking statements about its products, development timelines, market potential and cash runway are subject to significant risks and uncertainties.
Crinetics Pharmaceuticals’ Chief Commercial Officer, Isabel Kalofonos, reported routine insider transactions. On January 5, 2026, she exercised a stock option for 2,500 shares of common stock at an exercise price of $40.59 per share, converting derivative securities into common stock. That same day, she sold 2,500 shares of common stock in an open‑market transaction at $55.00 per share under a pre‑arranged Rule 10b5‑1 trading plan adopted on June 7, 2025.
Following these transactions, Kalofonos directly beneficially owned 834 shares of common stock, which include shares acquired under the company’s employee stock purchase plan, and held 97,500 stock options after the reported option exercise.
Crinetics Pharmaceuticals, Inc. entered into an underwriting agreement to issue and sell 7,620,000 shares of its common stock at a public offering price of $45.95 per share, with underwriters purchasing at $43.42275 per share. The company also granted the underwriters a 30-day option to buy up to 1,143,000 additional shares.
The company expects net proceeds of approximately $330.2 million from the offering, or approximately $379.8 million if the option is exercised in full, after underwriting discounts, commissions and estimated expenses. The offering, made under an effective shelf registration statement on Form S-3ASR, is expected to close on January 8, 2026, subject to customary closing conditions.
Crinetics Pharmaceuticals is raising equity capital by offering 7,620,000 shares of common stock at $45.95 per share. The gross proceeds are $350,139,000, with underwriting discounts and commissions of $19,257,645, resulting in estimated net proceeds of about $330.2 million, or $379.8 million if underwriters fully exercise their 1,143,000-share option. The company plans to use the cash, together with existing funds, to support the commercial launch of PALSONIFY, advance research and development across its endocrine-focused pipeline, and for general corporate purposes, including possible future in-licensing or acquisitions.
As of September 30, 2025, Crinetics had 94,548,323 shares outstanding. The company reports preliminary, unaudited net product revenue from PALSONIFY of more than $5.0 million for the quarter ended December 31, 2025 and estimates it held approximately $1.0 billion in cash, cash equivalents and investment securities as of that date. Based on the $45.95 offering price, new investors face immediate dilution of $32.22 per share, as net tangible book value is expected to rise from $11.34 to $13.73 per share after the offering.
Crinetics Pharmaceuticals, Inc. reported that Dana Pizzuti, M.D. will step down as Chief Medical and Development Officer effective December 31, 2025. Under a Transition and Separation Agreement, she will serve as a Strategic Regulatory and Development Advisor from January 1, 2026 through up to March 31, 2026. She will receive $577,000 in cash severance, eligibility for a 2025 annual bonus and a prorated 2026 bonus, up to $15,000 of legal fee reimbursement, up to 12 months of COBRA premium reimbursements, and up to $6,500 for a board training course.
Crinetics and Dr. Pizzuti also entered into an Advisor Agreement under which she will provide 10–20 hours per month of services from April 1, 2026 through up to March 30, 2028 for $600 per hour plus expense reimbursement. Certain existing equity awards will continue to vest during this advisory period, with additional vesting protections upon a Change in Control if specified conditions are met. Vested stock options may remain exercisable for up to three years after advisory service ends, subject to a ten-year maximum term.
Crinetics Pharmaceuticals (CRNX) reported Q3 2025 results and its first FDA approval. The FDA approved PALSONIFY (paltusotine) on September 25, 2025 for adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. The quarter did not include product sales.
Revenue was $143 thousand, primarily from a Japan license. Operating expenses rose with commercialization and pipeline spend: research and development $90.5 million and selling, general and administrative $52.3 million. Net loss was $130.1 million (basic and diluted loss per share $1.38), compared with a $76.8 million loss a year ago. Other income was $12.5 million, reflecting interest on investments.
Cash, cash equivalents and investment securities totaled $1.09 billion as of September 30, 2025, and management believes this is sufficient for at least 12 months. The company advanced atumelnant in CAH and ADCS and prepared an SST2-targeted NDC (CRN09682) Phase 1/2 start. Shares outstanding were 94,891,840 as of October 28, 2025.